News

CES 2024, themed “AI in Everything,” has prompted various industries to explore interdisciplinary integration, with the AI medical sector serving as a prominent example. Moderna, a pharmaceutical tech giant, has …

Bluebird bio’s CEO, Andrew Obenshain, defends the 40% premium on the list price of the gene therapy Lyfgenia compared to competitors Vertex and CRISPR Therapeutics. Obenshain highlights the outcomes-based contracts, …

In a groundbreaking study published in the Proceedings of the National Academy of Sciences, a team of Chinese scientists introduced an innovative approach to aging and disease prediction. Utilizing a …

Delve into the latest advancements in Sickle Cell Disease therapies with DelveInsight’s comprehensive report. Covering FDA, EMA, and PDMA approvals, clinical trials, mechanisms, and key companies like Bellicum Pharmaceuticals, Novartis, …

Patients with sickle cell disease (SCD) often grapple with diminished quality of life and a reduced life expectancy. The primary curative treatment, allotransplantation, carries risks, including transplant-related mortality. Gene therapy, …

In the transformative landscape of healthcare, 2023 emerged as a pivotal year for artificial intelligence (AI). With breakthroughs impacting both medical practices and patient experiences, AI became an integral part …

The Food and Drug Administration (FDA) has granted approval for a groundbreaking treatment for sickle cell disease, a debilitating condition affecting over 100,000 Americans, primarily from the Black community. Developed …

AstraZeneca, the pharmaceutical company renowned for developing one of the COVID-19 vaccines, has entered into a partnership with Absci, a U.S.-based artificial intelligence (AI) biologics firm. The collaboration involves an …

AB Science SA has announced that its masitinib in sickle cell disease is among the 19 projects to be funded under the “Hospital-University Research in Health” program. This program, part …